SCHEMBL4239498

SCHEMBL4239498

C[C@H](NC(=O)c1ccc(C(=O)N2CCC[C@H]2CN(C)C)c(Cl)c1)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.42
HSD11B1 P28845 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
PRCP P42785 5/20 0.38
OPRK1 P41145 1/20 0.38
ALDH1A1 P00352 2/20 0.37
DDR1 Q08345 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALOX12 P18054 1/20 0.35
APOBEC3A P31941 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
GRM5 P41594 1/20 0.34
GAA P10253 1/20 0.34
PLD2 O14939 1/20 0.34
PLD1 Q13393 1/20 0.34
PRSS12 P56730 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000802 1.00 TDP1 (0.42) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL6523977 1.00 TDP1 (0.42) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL5110309 0.94 HSD11B1 (0.41) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL14177350 0.92 TDP1 (0.43) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL5103935 0.92 TDP1 (0.43) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL5110179 0.92 TDP1 (0.43) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL3003473 0.92 TDP1 (0.43) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL2997160 0.92 TDP1 (0.43) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL5104101 0.92 TDP1 (0.43) TDP1HSD11B1L3MBTL1KDM4ELMNA
SCHEMBL5100460 0.91 HSD11B1 (0.42) TDP1HSD11B1L3MBTL1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases EISERT WOLFGANG 2009-03-19 US claimed
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases EISERT WOLFGANG 2009-03-19 US disclosed
US-20090048173-A1 Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors EISERT WOLFGANG 2009-02-19 US disclosed
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-06-05 US disclosed
US-7326791-B2 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 TDP1 1525/4885HSD11B1 964/4885L3MBTL1 4590/4885
US-20090048173-A1 Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors ANXA5, F5, ANXA3 TDP1 1000/4885HSD11B1 3466/4885L3MBTL1 4624/4885
US-20090075949-A1 Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases PEPD, PLAT, TFPI TDP1 153/4885HSD11B1 1599/4885L3MBTL1 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.